Lilly to Present CYRAMZA® (ramucirumab) Data at 2015 ASCO Annual Meeting (NYSE:LLY)

INDIANAPOLIS, May 28, 2015 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced that data from several trials of CYRAMZA^® (ramucirumab) will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, including a Phase II study of non-small cell lung cancer (NSCLC) patients in Japan. Other data, including those from global Phase III studies of CYRAMZA in gastric, non-small cell lung, and hepatocellular cancers, will also be presented at the meeting.   



Lilly to Present CYRAMZA® (ramucirumab) Data at 2015 ASCO Annual Meeting (NYSE:LLY)